Follow-up surveillance strategies for genitourinary malignancies

被引:12
作者
Evans, CP [1 ]
机构
[1] Univ Calif Davis, Dept Urol, Sch Med, Sacramento, CA 95817 USA
关键词
urologic cancer follow-up; prostate cancer; bladder cancer; renal cell cancer; testicular cancer; cancer surveillance;
D O I
10.1002/cncr.10525
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Genitourinary cancers account for more than 20% of all malignancies in the United States. These cancers do not usually yield rapid mortality, thereby necessitating longer-term surveillance strategies. METHODS. A review and analysis of relevant studies were performed, Follow-up strategies are proposed to reflect effective methods to detect recurrent prostate, bladder, renal, and testicular cancers. Cost analysis was performed using Medicare reimbursement rates. RESULTS. For genitourinary tumors, follow-up tests can be planned rationally based on detection rates and patterns. Tumor grade and stage drive follow-up strategies, along with therapeutic implications of detecting a recurrence. Symptomatic recurrences often obviate the need for radiographic tests and can minimize costs. Stage-specific plans for these four urologic malignancies are outlined specifically. CONCLUSIONS. Not all surveillance approaches have been critically tested for follow-up of genitourinary tumors, but ample data are available to propose sound medical and economic strategies. (C) 2002 American Cancer Society.
引用
收藏
页码:2892 / 2905
页数:14
相关论文
共 67 条
[1]  
*AM CANC SOC, 2000, AM CANC SOC STAT
[2]  
*AM CANC SOC, 2000, SURV RES SURV EP END
[3]  
[Anonymous], 1997, Br J Urol, V79, P235
[4]   Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen [J].
Anscher, MS .
INTERNATIONAL JOURNAL OF CANCER, 2001, 96 (02) :91-93
[5]   Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years [J].
Anscher, MS ;
Clough, R ;
Dodge, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :369-375
[6]   LATE RELAPSE OF CLINICAL STAGE-I TESTICULAR CANCER [J].
BANIEL, J ;
FOSTER, RS ;
EINHORN, LH ;
DONOHUE, JP .
JOURNAL OF UROLOGY, 1995, 154 (04) :1370-1372
[7]   Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results [J].
Catalona, WJ ;
Smith, DS .
JOURNAL OF UROLOGY, 1998, 160 (06) :2428-2434
[8]   Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy [J].
Cher, ML ;
Bianco, FJ ;
Lam, JS ;
Davis, LP ;
Grignon, DJ ;
Sakr, WA ;
Banerjee, M ;
Pontes, JE ;
Wood, DP .
JOURNAL OF UROLOGY, 1998, 160 (04) :1387-1391
[9]   The treated natural history of high risk superficial bladder cancer: 15-year outcome [J].
Cookson, MS ;
Herr, HW ;
Zhang, ZF ;
Soloway, S ;
Sogani, PC ;
Fair, WR .
JOURNAL OF UROLOGY, 1997, 158 (01) :62-67
[10]   Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? -: Results of a study in 50 patients [J].
Cremerius, U ;
Wildberger, JE ;
Borchers, H ;
Zimny, M ;
Jakse, G ;
Günther, RW ;
Buell, U .
UROLOGY, 1999, 54 (05) :900-904